Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)

被引：0

作者：

Krueger, Klaus ^{[1
]}

Selmi, Carlo ^{[2
,3
]}

Cantagrel, Alain ^{[4
]}

Abad, Miguel A. ^{[5
]}

Freudensprung, Ulrich ^{[6
]}

Rezk, Mourad Farouk ^{[6
]}

Addison, Janet ^{[7
]}

机构：

[1] Med Ctr Rheumatol, Munich, Germany

[2] Humanitas Res Hosp, Rheumatol & Clin Immunol Unit, Rozzano, MI, Italy

[3] Univ Milan, B1OMETRA Dept, Milan, Italy

[4] CHU, Ctr Rheumatol, Toulouse, France

[5] Hosp Virgen Puerto, FEA Reumatol, Caceres, Spain

[6] Biogen Int GmbH, Zug, Switzerland

[7] Biogen Idec Inc, Maidenhead, Berks, England

来源：

ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2537

引用

页数：2

共 40 条

[31] Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study
Panagiotis Athanassiou
Dimitrios Psaltis
Athanasios Georgiadis
Gkikas Katsifis
Athina Theodoridou
Souzana Gazi
Prodromos Sidiropoulos
Maria G. Tektonidou
Andreas Bounas
Anna Kandyli
Periklis Vounotrypidis
Grigorios T. Sakellariou
Dimitrios Vassilopoulos
Zhiping Huang
Evangelia Petrikkou
Dimitrios Boumpas
Rheumatology International, 2023, 43 : 1871 - 1883
[32] Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active)
Dejaco, Christian
Mueller, Thomas
Zamani, Omid
Kurtz, Ulrike
Egger, Stefan
Passini, Johannes Resch
Totzauer, Anna
Eisterer, Wolfgang
Yazdani-Biuki, Babak
Schwingenschloegl, Thomas
Peichl, Peter
Kraus, Angelika
Naerr, Gerhard
Rickert, Verena
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[33] Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study
Nuesslein, Hubert G.
Alten, Rieke
Galeazzi, Mauro
Lorenz, Hanns-Martin
Boumpas, Dimitrios
Nurmohamed, Michael T.
Bensen, William G.
Burmester, Gerd R.
Peter, Hans-Hartmut
Rainer, Franz
Pavelka, Karel
Chartier, Melanie
Poncet, Coralie
Rauch, Christiane
Le Bars, Manuela
BMC MUSCULOSKELETAL DISORDERS, 2014, 15
[34] Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study
Hubert G Nüßlein
Rieke Alten
Mauro Galeazzi
Hanns-Martin Lorenz
Dimitrios Boumpas
Michael T Nurmohamed
William G Bensen
Gerd R Burmester
Hans-Hartmut Peter
Franz Rainer
Karel Pavelka
Melanie Chartier
Coralie Poncet
Christiane Rauch
Manuela Le Bars
BMC Musculoskeletal Disorders, 15
[35] Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
Bingham, Clifton O.
Black, Shawn
Shiff, Natalie J.
Xu, Stephen
Langholff, Wayne
Curtis, Jeffrey R.
RHEUMATOLOGY AND THERAPY, 2023, 10 (03) : 659 - 678
[36] Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
Clifton O. Bingham
Shawn Black
Natalie J. Shiff
Stephen Xu
Wayne Langholff
Jeffrey R. Curtis
Rheumatology and Therapy, 2023, 10 : 659 - 678
[37] Abatacept Retention Rates and Prognostic Factors of Retention in Patients with Rheumatoid Arthritis (RA) Treated in Canada: 2-Year Results from a Real-World Observational Study
Haraoui, Boulos
Choquette, Denis
Bessette, Louis
Khraishi, Majed
Maoui, Meryem
Heitzmann, Julia
Connolly, Sean
Alten, Rieke
JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) : 980 - 980
[38] Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studies (the GO-BEYOND program)
Govoni, M.
Batalov, A.
Boumpas, D.
D'Angelo, S.
De Keyser, F.
Flipo, R. -M
Kellner, H.
Leroi, H.
Khalifa, A.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (03) : 642 - 650
[39] Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study
D'Angelo, Salvatore
Tirri, Enrico
Giardino, Angela Maria
De Rosa, Tiziana
Matucci-Cerinic, Marco
Dagna, Lorenzo
Santo, Leonardo
Ciccia, Francesco
Frediani, Bruno
Govoni, Marcello
Pallavicini, Francesca Bobbio
Grembiale, Rosa Daniela
Sedie, Andrea Delle
Mule, Rita
Cantatore, Francesco Paolo
Foti, Rosario
Gremese, Elisa
Conigliaro, Paola
Salaffi, Fausto
Viapiana, Ombretta
Cauli, Alberto
Giacomelli, Roberto
Arcarese, Luisa
Guggino, Giuliana
Russo, Romualdo
Puenpatom, Amy
Capocotta, Domenico
Nacci, Francesca
Anelli, Maria Grazia
Picerno, Valentina
Binetti, Corrado
Iannone, Florenzo
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (03)
[40] Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study
Reding, Mark T.
Alvarez Roman, Maria Teresa
Sanabria, Martin
Castaman, Giancarlo
Janbain, Maissaa
Matsushita, Tadashi
Meijer, Karina
Schmidt, Kathrin
Oldenburg, Johannes
BLOOD, 2022, 140 : 5612 - 5614

← 1 2 3 4 →